Trials / Terminated
TerminatedNCT01277510
Pediatric Chronic Kidney Disease Safety and Efficacy
A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the current treatment of secondary hyperparathyroidism in children currently receiving dialysis compared to a treatment regimen that does not include cinacalcet.
Detailed description
Secondary hyperparathyroidism (SHPT) is a condition that can develop early in patients with chronic kidney disease (CKD), usually gets worse over time, and is known to cause problems for patients on dialysis. Children on dialysis can have a wide range of bone and growth issues, and common treatments have a chance of making these things worse by increasing serum calcium and serum phosphorus. Cinacalcet has been shown to be effective in controlling parathyroid hormone (PTH), calcium and phosphorus in adults. The purpose of this study is to show that including cinacalcet in the treatment of SHPT will lower the levels of intact parathyroid hormone (iPTH) in a larger number of pediatric patients with CKD who are receiving dialysis, compared to a treatment regimen that does not include cinacalcet.
Conditions
- Chronic Kidney Disease
- Hyperparathyroidism
- Hyperparathyroidism, Secondary
- Kidney Disease
- Secondary Hyperparathyroidism
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cinacalcet capsule | Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing. |
| DRUG | placebo | Placebo tablets and capsules for sprinkling identical to active treatment. |
| DRUG | Standard of Care | All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician. |
Timeline
- Start date
- 2011-06-28
- Primary completion
- 2014-04-30
- First posted
- 2011-01-17
- Last updated
- 2020-06-29
- Results posted
- 2015-05-15
Locations
51 sites across 10 countries: United States, Australia, Belgium, Germany, Hungary, Mexico, Poland, Russia, Slovakia, Spain
Source: ClinicalTrials.gov record NCT01277510. Inclusion in this directory is not an endorsement.